A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of ...

A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, ...

Initial ADT reduced PSA from 78 to 17 ng/mL and improved pain score from 6/10 to 3/10 Abiraterone acetate (1000 mg daily with 5 mg prednisone twice a day) further suppressed PSA to 9 ng/mL Patient ...

Paul E. Dato, MD, discusses how when selecting abiraterone for metastatic hormone-sensitive prostate cancer patients, there are 3 formulations to consider: standard, generic, and micronized versions, ...

The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...

Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...

John Michael DiBianco, MD, discusses findings from the BLUES trial. A recent study evaluated silicone vs polyurethane stents found that the primary outcome of pain intensity and interference at 7 to ...

The miR Sentinel Prostate Cancer Test is a standalone liquid biopsy urine test. In an interview with Urology Times®, Nitin K. Yerram, MD, discusses the miR Sentinel Prostate Cancer Test, which is a ...

The intervention program modestly increased urine production but did not significantly reduce recurrent stone events compared to standard care. Participants in the intervention arm received a "fluid ...

A panelist discusses how they would communicate these comparative study results to patients by explaining that both enzalutamide and darolutamide effectively control metastatic prostate cancer when ...

Omitting stents post-ureteroscopy improves patient-reported outcomes, including pain and quality of life, without increasing complications. The trial showed no significant differences in 30-day ...

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.